Evaluating Prognostic Models for Survival in Metastatic Renal and Urothelial Cancers Treated with Immunotherapy

Overview

This study retrospectively assessed 120 patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC) treated with immunotherapy (IO) to evaluate four prognostic scoring systems—mGPS, SII, NLR, and NER—for predicting overall survival (OS). The systemic immune-inflammation index (SII) demonstrated the best discrimination for OS, suggesting its potential utility in clinical practice for guiding treatment decisions.

Background

Immunotherapy has become the standard of care for metastatic renal and urothelial cancers, offering manageable adverse events and improved outcomes. However, not all patients benefit equally from IO, necessitating reliable prognostic biomarkers to predict treatment response and optimize therapy. Blood-based scoring systems such as neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), neutrophil-to-eosinophil ratio (NER), and modified Glasgow prognostic score (mGPS) have been investigated for their prognostic value. This study aims to identify the most reliable prognostic model for routine clinical use in metastatic urological cancers treated with IO.

Data Highlights

Key Findings

• SII showed the best prognostic discrimination for overall survival with an AUC of 0.68 in ROC analysis.
• Higher baseline SII and NLR values were associated with worse overall survival in patients treated with IO.
• Lower neutrophil-to-eosinophil ratio (NER) correlated with improved survival outcomes in mRCC patients receiving IO.
• Modified Glasgow prognostic score (mGPS) provided additional prognostic information complementary to radiologic staging.
• Patients with mUC were older and had more prior systemic therapies compared to mRCC patients, who were more often therapy naive.
• Use of these scoring systems may help avoid overtreatment and enable early therapy optimization in metastatic urological cancers.

Clinical Implications

The systemic immune-inflammation index (SII) can be considered a reliable and easy-to-use prognostic biomarker for overall survival in metastatic renal and urothelial cancer patients undergoing immunotherapy. Incorporating SII and other blood-based scores such as NLR, NER, and mGPS into routine clinical assessment may guide treatment decisions, helping to identify patients unlikely to benefit from IO and reducing unnecessary healthcare burden. Early identification of high-risk patients could facilitate timely therapy adjustments and improve outcomes.

Conclusion

Among evaluated prognostic models, SII demonstrated superior predictive value for overall survival in metastatic renal and urothelial cancer patients treated with immunotherapy. Implementation of SII and related scoring systems in clinical practice may enhance personalized treatment strategies and optimize patient management.

References

1. SAUL Trial -- Atezolizumab Safety in mUC
2. ARON-1 Study -- SII in mRCC Patients
3. Immunotherapy Adverse Events Overview
4. Enfortumab Vedotin and Pembrolizumab Approval
5. mGPS Prognostic Value in Urological Cancers